For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

New data hint at a role for the AS01 adjuvant in vaccines for herpes zoster and respiratory syncytial virus in protecting ...

By Hugo Francisco de Souza New research reveals that vaccines enhanced with the AS01 adjuvant may help shield the aging brain ...

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Some members of the scientific community have concern that they’re coming out of the COVID pandemic—exposure to the virus, ...

Dr. Todd Ellerin, Vice Chair of Department of Medicine of South Shore Health discusses the new FDA warning regarding Pfizer and Moderna COVID-19 vaccines.The FDA is expanding warnings on Pfizer and ...

The committee chair hinted at banning MMR shots for certain children, said Naomi Rogers, a science historian at Yale University.

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.